CURRICULUM VITAE Miguel Goicoechea, M.D. Office: Telephone: University of California at San Diego Antiviral Research Center 150 West Washington Street, Suite 100 San Diego, CA 92103-2005 (619) 543-8080 (work) (619) 955-2378 (mobile) Fax: (619) 298-0177 E-mail: Citizenship: Languages: mgoicoechea@ucsd.edu U.S.A. Bilingual: English-Spanish Education 1989-1993 B.A. Biology. University of Southern California, Los Angeles, CA 1994-1998 M.D., Howard University School of Medicine, Washington, D.C. 1998-2001 Intern and Resident in Internal Medicine. Mount Sinai Medical Center, Miami Beach, FL Internal Medicine Program Director: Gloria Weinberg, M.D. 2002-2006 Postdoctoral Fellow Infectious Diseases. University of California at San Diego, San Diego, CA Division Chair: Robert Schooley, M.D. Academic Positions 2001-2002 Clinical Investigator. University of Miami School of Medicine AIDS Clinical Research Center, Miami, FL Director: Margaret Fischl, M.D. 2006-2008 Clinical Instructor. University of California at San Diego, San Diego, CA Division of Infectious Diseases Chair: Robert Schooley, M.D. 2008-present Assistant Adjunct Professor of Medicine. University of California at San Diego; Division of Infectious Diseases; San Diego, CA Chair: Robert Schooley, M.D. Honors - Awards 1992 NIH Summer Research Fellowship Recipient 1999 Resident s Choice for Intern of the Year 1
2003 Ortho Biotech ID Fellows Scholarship Award 2004 Bristol-Myers Squibb Virology Research Program Recipient 2003-2006 NIH AIDS Training Grant Fellowship 2004-2008 NIH Clinical Research Loan Repayment Program Recipient Board Certification Diplomate, American Board of Internal Medicine; 2001 Diplomate, American Board of Internal Medicine Infectious Diseases; 2005 Licensures Florida (ME8061) 1999 1/2005 California (A78023) 2002 - present Hospital Appointments 2001-2002 Mount Sinai Medical Center; Miami Beach, FL 2006-present University California San Diego; San Diego, CA Clinical Practice Interests 1. In-patient care of immune compromised hosts 2. HIV-infected individuals 3. HIV-Hepatitis C co-infection treatment Research Interests 1. Immune reconstitution in the context of potent antiretroviral therapy 2. Nucleoside pharmacology Editorial Experience 2008 Ad hoc reviewer for 2007 Ad hoc reviewer for Journal of Acquired Immunodeficiency Syndrome Ad hoc reviewer for Journal of Infectious Diseases Ad hoc reviewer for Journal of Antimicrobial Chemotherapy Ad hoc reviewer for Drugs of Today Ad hoc reviewer for HIV Clinical Trials Ad hoc reviewer for Therapeutics and Clinical Risk Management 2006 Ad hoc reviewer for Human Immunology Ad hoc reviewer for Expert Opinion on Pharmacotherapy Publications 1. Goicoechea M, Fierer J, Johns S. Treatment of Candidal Cholangitis with Caspofungin in a Liver Transplant Patient: Documentation of Caspofungin Biliary Excretion (Research Letter). Clinical Infectious Diseases 2004 Apr 1; 38(7):1040-1041. 2
2. Goicoechea M and Haubrich RH. CD4 T Cell Percentage Versus Absolute CD4 T Cell Count in Predicting HIV Disease Progression: An Old Debate Revisited (Editorial Commentary). Journal of Infectious Diseases 2005; Sept 15; 192(6): 945-947. 3. Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD, Diamond C, Tilles JG, Kemper CA, Larsen R, Goicoechea M, Haubrich RH, and the California Collaborative Treatment Group (CCTG). Cognitive-Behavioral Intervention to Enhance Adherence to ART: A Randomized Controlled Trial (CCTG 578). AIDS 2006 Jun 12; 20(9): 1295-1302. 4. Goicoechea M, Best B, Seefried E, Wagner G, Capparelli E, Haubrich and the California Collaborative Treatment Group. Failure of Modified Directly Observed Therapy Combined with Therapeutic Drug Monitoring to Enhance Antiretroviral Adherence in a Patient with Major Depression (Case Report). AIDS Patient Care and STDs 2006 Apr; 20(4): 233-237. 5. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, and Haubrich R. Determinants of CD4+ T-cell Recovery during Suppressive Antiretroviral Therapy: Association of Immune Activation, T-cell Maturation Markers and Cellular HIV-1 DNA. Journal of Infectious Diseases 2006; Jul 1; 194(1): 29-37. 6. Goicoechea M, Best B, Capparelli E, Haubrich R and the California Collaborative Treatment Group. Concurrent Use of Efavirenz and Oxcarbazepine May Not Affect Efavirenz Plasma Concentrations (Research Letter). Clinical Infectious Diseases 2006 Jul 1; 43(1):116-117. 7. Goicoechea M, Best B, Capparelli E, Caperna J, Ballard C, and Haubrich R. Therapeutic Ritonavir-Boosted Atazanavir Plasma Levels During Concurrent Omeprazole Use (Research Letter). AIDS 2006 Oct 24; 20(16): 2127-8. 8. Goicoechea M and Best B. Efavirenz/ emtricitabine/ tenofovir disoproxil fumarate fixed-dose combination: First-line therapy for all? (Review Article). Expert Opinion on Pharmacotherapy 2007 Feb; 8(3): 371-382. 9. Goicoechea M. Human H5N1 Influenza (Correspondence). New England Journal of Medicine 2007 Mar 29; 356(13):1375. 10. Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Diamond C, Witt MD, Haubrich R, and the California Collaborative Treatment Group (CCTG). A Computer-Based System to Aid in the Interpretation of Plasma Concentrations of Antiretroviral Agents for Therapeutic Drug Monitoring. Antiviral Therapy 2007; 12(1): 55-62. 11. Best BM, Goicoechea M, Witt M, Miller L, Daar E, Diamond C, Tilles J, Kemper C, Larsen R, Holland DT, Sun S, Wagner G, Capparelli EV, McCutchan JA, Haubrich R and the California Collaborative Treatment Group (CCTG). A Randomized Controlled Trial of Therapeutic Drug Monitoring in Treatment-Naïve and Experienced HIV-1-Infected Patients (CCTG 578). Journal of Acquired Immunodeficiency Syndrome 2007; 46: 443-442. 3
12. Goicoechea M and Smith DM. Universal HIV Testing Is It Enough? (Editorial Commentary). Clinical Infectious Diseases 2007; Nov 15 (45): 1375. 13. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S and the CCTG 578 Team. Greater Tenofovir-Associated Renal Function Decline in Protease Inhibitor- versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Therapy. Journal of Infectious Diseases 2008; Jan 1 (197): 102-108. 14. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S and the CCTG 578 Team. Tenofovir-associated renal function decline (Author s Response). Journal of Infectious Diseases 2008; [in press]. 15. Best B and Goicoechea M. Efavirenz: Still First-Line King? (Review Article). Expert Opinion on Pharmacotherapy 2008; [in press]. Book Chapters 1. Goicoechea M, Haubrich R. Chapter 18: Nelfinavir. In: AIDS Therapy 3rd Edition Copyright 2007. Editors: Dolin R, Masur H, Saag MS. Elsevier Science: USA. Presented Abstracts 1. Castro JG, Goicoechea M, Monroig R, Ale-Castro MG. Prior participation in clinical trials as a predictor of virologic success in patients followed in a specialized HIV clinic. (Abstract WePeB5840) 14 th International AIDS Conference; July 7-12, 2002: Barcelona, Spain. 2. Goicoechea M, Miller C, Spina C, Currier J, Kemper C, Witt M, Leedom J, Forthal D, Keiser P, McCutchan JA, Richman D, Haubrich R, and California Collaborative Treatment Group (CCTG). Quantitative CD38 Expression on CD8 T-Cells as a Predictor of CD4 T-Cell Maintenance Among Patients Failing Salvage Antiretroviral Therapy. (Abstract: 290) 11 th Conference of Retroviruses and Opportunistic Infections; February 8-11, 2004: San Francisco, USA. 3. Goicoechea M, Landay A, Miller C, Smith D, Haubrich R and the California Collaborative Treatment Group. Immune Activation Predicts Immunologic Discordance in Patients with Virologic Control During Antiretroviral Therapy (Abstract MoPeA3079). 15 th International AIDS Conference; July 11-17, 2004: Bangkok, Thailand. 4. Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Larsen R, Diamond C, Witt M, Haubrich R, and California Collaborative Treatment Group. A Computer Artificial Intelligence System to Aid in the Interpretation of Plasma Lopinavir (LPV) and Efavirenz (EFV) Drug Concentrations. (Abstract: 641). 12 th Conference of Retroviruses and Opportunistic Infections; February 22-25, 2005: Boston, MA. 4
5. Haubrich R, Best B, Witt M, Goicoechea M, Kemper C, Larsen R, Diamond C, Heseltine P, Capparelli E, Wagner G, McCutchan JA, and the California Collaborative Treatment Group. Determinants of the Need for Therapeutic Drug Monitoring (TDM): Rates and Predictors from CCTG 578. (Abstract: 640). 12 th Conference of Retroviruses and Opportunistic Infections; February 22-25, 2005: Boston, MA. 6. Best B, Witt M, Goicoechea M, Kemper C, Larsen R, Diamond C, Capparelli E, Wagner G, McCutchan JA, Haubrich R and the California Collaborative Treatment Group. Improved Antiretroviral Exposure with Therapeutic Drug Monitoring. (Abstract: 589) 13 th Conference of Retroviruses and Opportunistic Infections; February 4-9, 2006: Denver, CO. 7. Goicoechea M, Spina C, Currier J, Kemper C, Witt M, Leedom J, Forthal D, McCutchan JA, Richman D, Haubrich R and the California Collaborative Treatment Group. CD4 T-cell Maintenance in Treatment-Experienced Patients with Viral Failure: Association of Nadir CD4 T-cell Count, Immune Activation, and Replication Capacity. (Abstract: 422). 13 th Conference of Retroviruses and Opportunistic Infections; February 4-9, 2006: Denver, CO. 8. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S and the CCTG 578 Team. Increased Renal Impairment in Patients Receiving Tenofovir Disoproxil Fumarate (TDF) + Protease Inhibitors versus TDF + Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (Abstract: 835). 14 th Conference of Retroviruses and Opportunistic Infections; February 25-28, 2007: Los Angeles, CA. 9. Goicoechea M, Louie L, [USC lab], Jain S, Sun S, [GSK] and Haubrich R and the California Collaborative Treatment Group. Measurement Variability in Specimen Processing and Mass Spectrometric Analysis of Intracellular Carbovir Triphosphate Concentrations (Abstract: P45). 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008: New Orleans, LA. 5